97. Ulcerative colitis
2,269 clinical trials,   1,331 drugs   (DrugBank: 241 drugs),   114 drug target genes,   181 drug target pathways

Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2019-001430-33-DE
(EUCTR)
18/06/202025/02/2020A clinical trial to see if GS-4875 is effective and safe in treating people with moderate to severe ulcerative colitisA Phase 2, Blinded, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-4875 in Subjects with Moderately to Severely Active Ulcerative Colitis ulcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]Product Code: GS-4875
Product Code: GS-4875
Gilead Sciences, Inc.NULLNot RecruitingFemale: yes
Male: yes
180Phase 2United States;Austria;Russian Federation;Switzerland;United Kingdom;Italy;France;Czech Republic;Canada;Belgium;Poland;Australia;Germany
2EUCTR2019-001430-33-AT
(EUCTR)
15/05/202031/01/2020A clinical trial to see if GS-4875 is effective and safe in treating people with moderate to severe ulcerative colitisA Phase 2, Blinded, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-4875 in Subjects with Moderately to Severely Active Ulcerative Colitis Therapeutic area: Diseases [C] - Digestive System Diseases [C06]Product Code: GS-4875
Product Code: GS-4875
Gilead Sciences, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
180Phase 2United States;Austria;Russian Federation;Italy;Switzerland;United Kingdom;France;Czech Republic;Canada;Belgium;Poland;Australia;Germany
3EUCTR2019-001430-33-GB
(EUCTR)
05/05/202021/02/2020A clinical trial to see if GS-4875 is effective and safe in treating people with moderate to severe ulcerative colitisA Phase 2, Blinded, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-4875 in Subjects with Moderately to Severely Active Ulcerative Colitis ulcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]Product Code: GS-4875
INN or Proposed INN: to be confirmed
Product Code: GS-4875
INN or Proposed INN: to be confirmed
Gilead Sciences, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
180Phase 2United States;Czechia;Austria;Russian Federation;United Kingdom;Italy;Switzerland;France;Canada;Belgium;Poland;Australia;Germany
4EUCTR2019-001430-33-FR
(EUCTR)
02/04/202020/02/2020A clinical trial to see if GS-4875 is effective and safe in treating people with moderate to severe ulcerative colitisA Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-4875 in Subjects with Moderately to Severely Active Ulcerative Colitis ulcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]Product Code: GS-4875
Product Code: GS-4875
Gilead Sciences, Inc.NULLNot RecruitingFemale: yes
Male: yes
180Phase 2United States;Austria;Russian Federation;Italy;Switzerland;United Kingdom;France;Czech Republic;Canada;Belgium;Poland;Australia;Germany
5NCT04130919
(ClinicalTrials.gov)
December 20, 201916/10/2019Study to Evaluate the Efficacy and Safety of GS-4875 in Adults With Moderately to Severely Active Ulcerative ColitisA Phase 2, Blinded, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-4875 in Subjects With Moderately to Severely Active Ulcerative ColitisUlcerative ColitisDrug: GS-4875;Drug: PlaceboGilead SciencesNULLRecruiting18 YearsN/AAll180Phase 2United States;Australia;Austria;Canada;France;Germany;Italy;Poland;Switzerland